References
- Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671–84.
- Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004;31:2501–6.
- Bulatović M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 2011;63:2007–13.
- Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533–8.
- Amanzio M. Nocebo effects and psychotropic drug action. Expert Rev Clin Pharmacol 2015;8:159–61.
- Diamond A. Consequences of variations in genes that affect dopamine in prefrontal cortex. Cereb Cortex 2007;17:i161–70.
- Wendt L, Albring A, Benson S, Engler H, Engler A, Hinney A, et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PLoS One 2014;9:e107665.
- Scheuern A, Tyrrell PN, Haas J-P, Hugle B. Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect. Rheumatology (Oxford) in press.
- DeMille MM, Kidd JR, Ruggeri V, Palmatier MA, Goldman D, Odunsi A, et al. Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet 2002;111:521–37.